TauRx Pharmaceuticals Ltd.
16 articles about TauRx Pharmaceuticals Ltd.
-
Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
3/7/2024
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference in Lisbon, Portugal.
-
TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
2/5/2024
TauRx Pharmaceuticals Ltd. announced that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate at the upcoming AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
-
TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)
7/16/2023
TauRx Pharmaceuticals Ltd. announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain, an established biomarker for brain neurodegeneration.
-
TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.
-
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
11/30/2022
TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's.
-
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
11/14/2022
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy.
-
TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
10/6/2022
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease.
-
TauRx announced preliminary results from the Phase III study, showing HMTM, its potent inhibitor of tau aggregates, could slow Alzheimer's disease progression or cognitive decline.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
6/1/2022
TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer's, announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
TauRx's late-stage clinical trial reaches new milestone
4/14/2022
TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease research, has announced that the last patient has completed treatment in the blinded phase of their late-stage clinical trial, Lucidity.
-
TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.
-
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec
7/18/2017
-
TauRx Pharma's Much-Watched Alzheimer's Drug Flops in Trial
7/27/2016
-
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July
3/21/2016